Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC

Eli Lilly (LLY) seeks pediatric approval for Omvoh after positive Phase 3 trial results. 50% of pediatric ulcerative colitis patients achieved remission at 52 weeks. The company's GF Value suggests a 20.4% undervaluation, with a GF Score of 96/100. Insiders sold $2.66B in shares over the past year, while 25 gurus hold positions, with 12 adding and 10 trimming.

Metis TechBio, a Hong Kong-listed biotech, has partnered with Eli Lilly for up to $1.1 billion to develop AI-driven drug-delivery technologies. Metis will receive an upfront payment and potential milestone payments, plus royalties on sales. The collaboration aims to improve tissue targeting for LNP-based therapies.

Eli Lilly's experimental drug retatrutide, a triple hormone receptor agonist, showed significant weight loss in a Phase III trial. Participants with obesity and type 2 diabetes lost an average of 18.8% body weight over 80 weeks, with higher doses yielding even greater results. The drug targets GLP-1, GIP, and glucagon receptors, distinguishing it from competitors. FDA approval is anticipated next year.

Eli Lilly (LLY) plans to expand Omvoh's use for pediatric ulcerative colitis after a successful late-stage trial. The company aims to seek an indication extension for the therapy, which is currently approved for bowel disease. This follows a one-year study showing positive results in children with the inflammatory colon condition.

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

Eli Lilly (LLY) reported positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis, showing 81% clinical response and 50% remission rates. The company's GF Value™ suggests a 20.4% undervaluation, with a GF Score™ of 96/100. Insider selling totaled $2.66 billion over 12 months, while 25 gurus hold the stock with balanced activity. LLY's P/E ratio is 42.71x, below its 5-year median of 53.19x.